Clinical trial · Interventional
Comparison of CT-Guided Celiac Plexus Neurolysis and Pharmacotherapy
Comparison of Analgesic Effects of CT-Guided Celiac Plexus Neurolysis With Pharmacotherapy as Palliative Care of Upper Gastrointestinal Malignancies
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
After enrolment, patients were randomly assigned to two groups by means of a lottery procedure, whereby each patient blindly chose one of two labelled slips, resulting in group assignment to receive. Group A patients were subjected to CT-guided celiac plexus neurolysis, and Group B patients to standard pharmacotherapy for managing the pain over a period of four weeks. CT-guided celiac plexus neurolysis under the supervision of the principal investigator, using local anaesthetic and absolute ethanol injection for neurolysis, was carried out using aseptic technique. Baseline demographic information, which included age, gender, nature of malignancy, and the duration of disease, was recorded using a predesigned proforma. Pain severity was measured by the Visual Analogue Scale (VAS), a recognised 0-10 scale where 0 = no pain to 10 indicating the worst imaginable pain, at baseline and after 4 weeks of treatment. The major outcome measure was the average pain score at four weeks in both groups.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Upper Abdominal Malignancies | — | UNRESOLVED | — |
| Upper Gastrointestinal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT-guided celiac plexus neurolysis | Procedure | — | UNRESOLVED |
| Standard pharmacotherapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- CT-guided celiac plexus neurolysis
- interventionNames
- Procedure: CT-guided celiac plexus neurolysis
- type
- ACTIVE_COMPARATOR
- label
- Standard pharmacotherapy
- interventionNames
- Procedure: Standard pharmacotherapy
Primary outcomes (1)
- measure
- Average pain score at baseline and after 4 weeks of treatment
- timeFrame
- Baseline to 4 weeks
- description
- Pain severity was measured by the Visual Analogue Scale (VAS), a recognized 0-10 scale where zero is equivalent to no pain and 10 indicates the worst imaginable pain, at baseline and after 4 weeks of treatment.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy proven upper GI malignancy with severe abdominal pain * Patients aged 18 to 65 years of either gender Exclusion Criteria: * Pregnant and lactating females * Anemia (hemoglobin \<10 g/dL) * Massive ascites * Chronic renal failure * Patients with known allergy or intolerance to drugs used during celiac plexus neurolysis (CT guided technique).
References
Publications (2)
- BACKGROUNDDaniels M, Duran E, Pan V, Rentzepis P, An T, Thabet A, Hao D. Computed Tomography-Guided Celiac Plexus Block and Neurolysis: Technical Outcomes and Complications. Pain Physician. 2026 Jan;29(1):E59-E66. PMID 41628217
- BACKGROUNDFaghih M, Damm M, Bandhauer C, Jager J, Olesen SS, Laheru DA, Zheng L, Phillips AE, Yadav D, Drewes AM, Rosendahl J, Singh VK. Pancreatic adenocarcinoma patients with pain have abnormal central pain processing. Pancreatology. 2025 May;25(3):426-432. doi: 10.1016/j.pan.2025.04.010. Epub 2025 Apr 16. PMID 40382254